These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 8392487)

  • 21. Gastrointestinal endocrine cancers and nodal metastasis: biologic significance and therapeutic implications.
    Peplinski GR; Norton JA
    Surg Oncol Clin N Am; 1996 Jan; 5(1):159-71. PubMed ID: 8789500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin analogs in the management of gastrointestinal tumors.
    Lamberts SW
    Horm Res; 1988; 29(2-3):118-20. PubMed ID: 2900191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug therapy of endocrine neoplasms. Part II: Malignant gastrinomas, insulinomas, glucagonomas, carcinoids and other tumors].
    Schott M; Scherbaum WA; Feldkamp J
    Med Klin (Munich); 2000 Feb; 95(2):81-4. PubMed ID: 10714123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
    Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
    Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
    Maton PN; Gardner JD; Jensen RT
    Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.
    Fjällskog ML; Sundin A; Westlin JE; Oberg K; Janson ET; Eriksson B
    Med Oncol; 2002; 19(1):35-42. PubMed ID: 12025889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
    Van Eijck CH
    Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diagnostics and treatment in functional pancreatic neuroendocrine tumours].
    Müssig K; Dudziak K; Horger M; Anlauf M; Goretzki PE
    Dtsch Med Wochenschr; 2011 Jun; 136(24):1319-30. PubMed ID: 21656454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
    Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
    Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine tumors of the pancreas: the pathologist's approach.
    Bordi C
    Acta Biomed Ateneo Parmense; 1993; 64(5-6):195-204. PubMed ID: 7992557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
    Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
    Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors.
    Oda Y; Tanaka Y; Naruse T; Sasanabe R; Tsubamoto M; Funahashi H
    Surg Today; 2002; 32(8):690-4. PubMed ID: 12181718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide.
    Nocaudie-Calzada M; Huglo D; Deveaux M; Carnaille B; Proye C; Marchandise X
    J Nucl Med; 1994 Jan; 35(1):57-62. PubMed ID: 8271061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal neuroendocrine tumors.
    Delcore R; Friesen SR
    J Am Coll Surg; 1994 Feb; 178(2):187-211. PubMed ID: 8173736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunohistochemical and electron microscopic studies of diseases of the gastroenteropancreatic-endocrine system].
    Grube D; Hanser M
    Acta Histochem Suppl; 1984; 30():167-87. PubMed ID: 6326191
    [No Abstract]   [Full Text] [Related]  

  • 36. Octreotide.
    Lancet; 1989 Sep; 2(8662):541-2. PubMed ID: 2570240
    [No Abstract]   [Full Text] [Related]  

  • 37. [Mixed endocrine tumor of the pancreas (vipoma, glucagonoma). Treatment by somatostatin followed by one of its long-acting analogs].
    Kaloustian E; Guillauseau PJ; Chayvialle JA; Veyssier P; Lallement PY; Latrive JP; Zylberait D; Lubetzki J
    Presse Med; 1987 Dec; 16(44):2217-20. PubMed ID: 2893369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology.
    Camisa C
    Arch Dermatol; 1989 Mar; 125(3):407-12. PubMed ID: 2564269
    [No Abstract]   [Full Text] [Related]  

  • 39. Pancreatic endocrine tumors.
    Klöppel G; Heitz PU
    Pathol Res Pract; 1988 Apr; 183(2):155-68. PubMed ID: 2898775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
    Flückiger A; Schlup P
    Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.